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Over the past ten years, the basic scientific successes of bio-
technology have been brought closer to applications for a wide range 
of social and economic purposes, principally in health care and in 
agriculture. Throughout the world, new biotechnology products are now 
being brought to market. their benefits reaching patients, farmers and 
consumers. In the United States, public expenditure on biotechnology 
research amounts to$ 2.7 bn per year (1) motivated by a clear percep-
tion in scientific, economic and political circles of its importance 
to the future competitiveness of US exports. 
Within the EEC, action in biotechnology is one of tlte lines of the 
framework programme for Com11Unity activities in the field of research 
and technological development (2); the stated purpose being: 
"To master the properties of living cells and to secure 
their exploitation, in the interests of consumers, by both 
industry and agriculture". 
Past and current Community actions have aimed at strengthening the 
scientific base of Europe's ~iotechnology, and hence inter alia 
improving its international competitiveness. Through the Biomolecular 
Engineering Programme (1982-86) and the ongoing Biotechnology Action 
Program.me (1985-89}, the Community is stimulating a network for 
training and for transnational collaborative research in European 
Laboratories Without Walls (ELWW). Through collaboration with Member 
States, through other Community programmes and through a range of 
concertation activities including impact assessments, the Commission 
seeks to encourage the effective application of the fruits of bio-
technology to the social and economic objectives of the Comm.unity and 
its Member States- These ~bjectives include not only competitiveness, 
but th~ improvement of health and environment, and the promotion of 
scientific and industrial collaboration with developing countries. 
Objectives of the proposed programme 
The present proposal for a successor prograimne to BAP is in line with 
the above developments. Entitled BRIDGE (Biotechnology Research for 
Innovation, Development and Growth in Europe). it is planned for 
1990-94, with a total budget of 100 Mio ECU. 
The objectives of BRIDGE have been defined on the ba~is of past 
achievements in BEP and BAP and through recommendations received from 
a panel of Independent Experts~ the European Parliament. industrial 
organisations and.the CGC Biotechnology. 
BRIDGE is .subdivided, as was BAP ,- intcr:tvo actions : 
Action I for Research and Training, and Action II for accompanying 
actions grouped under the term "Concert:ation".. Ninety per cent of the 
total budget will be devoted to Action I and 10% to Action .II. 
ii 
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The main tasks of Action J tdll ~e. ·< to :de,relo.p .cooperative basic 
researcn and train1ug ttaro1.agt1 .t;e$ea:tch,,d·~pt~d .t~ the lon.g tepzi needs · 
of the Community. This implies, for:·the· ~ean.oval -,f bottlenecks t'esult.:. · 
ing from gaps in basic knowledge. the . reinforcement of existing 
networks of ELWWs and their extension to new areas considered of high 
significance for the Community. Alternatively, larger targeted pro-
je~ts will be implemented, when necessa,ey .. for. removing bottlenecks 
originating from scale or structural coMtraJnts. A very substantial 
effort is foreseen in the area of ~r.fn.ctrniat:!v~ reseatch ~d •.. in 
particular. with regard to the assessiJ:i~1.1t qf risks possibly associollted 
to the release of genetically engineered microorganisms. The research 
and training programme is subdivided into four sectors: 
- information infrastructure~ 
- enabli_l!g technologies 
- cellular biology 
·- pre-normative research 
Action II "Concertation" will cover a range :c:,f. monitoring. informatio~ 
and collaborative activit!es to provide and fa~~l<i~ate the effective 
application of biotechnology to the social and·. economic objectives of 
the Community and of the Member States. 
(1) U.S. Congressional Office.eof Technology Assessment, "U.S. 
Investment in Biotechnology" 11 April 1988. 
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ACTION I RES&\"<:ff AND TRAINING l 
i. BAS IS OF TIIE PRESENT PROPOSAL 
The argumentation for a continuation · of Community . R:&l) efforts in 
biotechnology and the choice of the main orientations iri the proposed 
programme are based upon: 
- the assessment. by the Commission servJ,e~,5-l:##.J>y i~depen-
dent experts. of past and ongoing R&D Community ·pi'~g,;c1011J1.es in- bi~--
molecular engineering and biotechnology 
.. 
- recommendations for future activities. as expressed by 
Com.mission and national experts. the European ParU.!llllf!ll~•>a panel of 
independent experts.--industrial bodies and--the 11.ait:lon~J._:::deleg.attoris 
of the CGC "Biotechnology". 





· The first R&D Community activi~ 111>: biOtf!clln~lo~;\W~U~ . BEP ·. (Bto-
molecular Engineering Pr9graDDDe)· · .· ~-tJt:; a. · b'1tige~ ·: C.lf i. lS .Mio . ECU. 
which supported !between Apr11 19.ai :J~n.d .Marc\-l?&tr::-::91. •-tr.~n:1n.1 
~ontracts and 103 ~st~si.areci ;~seat,~h- ~jitrac.ts.-:li..t.tb.- publi~ "and 
private laboratories in the Community.·· The secori.d R&D "programme in 
biotechnology is B•l' (Biotechnology Action_ Programme) which covers 
the period 1985 ~ 1989-. w:f.t;h:, a. b11dj~C :.c,l.}S.'.::l!fJ,;~f'~~~, :JJte le~earch 
activities of BAP are being __ e~-«:~te~:~:f9r<.tlte:·-.·t~e.:.::.~eb1g~>fn 90 
transnational projects by· gtoup~;· of :Jaix.>.~atoties ]1rhtcl\ :,agr:eea··~o 
jom their efforts and to w-ork togetb.e£.. · · · ·· · ... : .:. ·· · 
lDetailed information· on the im:,lewentatioll and. <S.chievements . of 
these tvo programmeg h~V® been pub~~S.\ed.: by.:' .t~- . C~m1$slon ser .... ·:--: 
.. ~·-· :.··:. . . 
vices (1 o 2e, 3) o · __ .,_ 
BEF has been submitted t@ ®Waluation. p1;c,c~d.~t:e§i •. :~a:~ed . oli,t . i~ · 
three different level$ g /fesearch contractors (l)J) CCC ''Bio.;_ 
technology" (4) o Pa.Kile! @f Iimdependent Experts nominated !by the 
Commissiono 
liomlecular Engineering :l~ tdle European Community : achievements 
of the research progr~ (1982-1986) •. edited by E. Magnien. 
Martinus Nijhoff Publishers foi:' -the COUUD1S$.1oa qf the European 
Communities, EUR 10658 EN• °19860 · . , > : · · 
!European Laooratories Vith@ut Walls · : · J,c:u.sed. _·_ .. pi'e~aip•t:(.tiv.e. · 
Ieesearch. a. van der Meer. l!o Magnien ~~~~'.··:Q:.~de --~tan.court: 
Trends in biotechnology (1987) 4: 217 o · · · ·. · '· 
3IOTECHNOLOGY ACIION PROGRAMMEo frogress ~eport 1987 ( 2 volumes) 0 
!Ed.: E .. Magnien.. Commlssioil. ~f the Europe!an ColDlllUnities 0 
EUR Hl38 EN• Lu.x:embu.rgo 1987 a The 1988 issnue will·I>~ published, in 
January 1989. · - · · 
COM(86) 272 final "Communication fr@m the Comm:(.ssion to the 
Council concerning the review of the mulUannual. reseatch · pro--
-gramme for the EEC in the field «!f ~fot~«:lmology''. 21 Kay 1986,. · , 
= 3 -
·'t 
BAP was assessed by the same Panel of Independent Experts who 
evaluated BEP (l). 
Every on~ ut the~~ ~valuaLions underlined the usefulness ot 
Community R&D in biotechnology. 
With regard to BEP, the CCC biotechnology considered that "its 
most convincing result is undoubtedly the creation of a climate 
favourable to transnational cooperation, the effects of which fall 
beyond the hopes expressed when the programme was launched" .. 
Commenting on both BEP and BAP, the Evaluation Panel of Indepen-
dent Experts stated that" .... a major achievement of the research 
programmes, and one that is important for the future, has been to 
break down national frontiers between laboratories. We comm.end the 
Commission's initiative in linking groups into European Labora-
tories Without Walls, a useful concept that could be applied in 
other domains. We were impressed by the way some contractors. who 
had initially been sceptical-about transnatio-nal cooperation.-were 
now enthusiastic". 
The Evaluation Panel concluded that the training activities in BEP 
and BAP had been successful and that the research programmes led 
to a number of substantial scientific achievements testifying for 
their high quality. The panel noted that "highly significant 
technical breakthroughs" ( 2) had been achieved by the programme 
particularly in sectors such as the genetics of plants and of 
industrial microorganisms. In sectors where such breakthroughs 
were not reached, the Panel considered that either the goals and 
bottlenecks . had been insufficiently defined or that a critical 
mass of researchers had not been assembled. 
1.2. Recommendations for future activities 
1 • ., ~l. Recommendations of the Evaluatton. Panel 
.................................... -.. 
The panel concluded its report ( l) by a number of recommen-
dations which, as far as the .... research activities of BRIDGE are 
concerned, call for "science-led" projects and "large scale" 
projects. 
The panel considered that the following large scale projects are 
of particular importance : 
11 
- To sequence the yeast genome completely. 
- To develop detailed molecular genetic maps for one plant and 
one animal species of economic importance to Europe. 
(1) Evaluation of the B°!onolecular Engineering Programme, BEP 
(1982-1986) and the Biotechnology Action Programme, BAP 
(1985-1989). Research Evaluation Report n° 32 - EUR 11833 EN/1. 
(2) It is of course on the basis of such breakthroughs, ultimate 
consequence of the catalytic effects of transnational.cooperation, 
that the programmes need to be judged. The complete list of 
scientific and technical achievements. which cannot be reproduced 
here, are to be found in the final report of BEP and in the last 
two annual reports of BAP (l.c.). 
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- To undertake a focused programme in protein engineering so as 
to understand and modify in a multi-disciplinary manner the 
structure and biological and/or physical properties of a few 
proteins. 
- To elucidate the control of gene stability, transcription, 
post-transcriptional and post-translational processing 1 
protein over-production, and secretion in one major industrial 
microorganism through genetic manipulation, biochemistry and 
cell physiology. 
- To apply recent progress in molecular biology to the physio-
logy and improvement of major European crops, including gene 
transfer to, and cell regeneration of, cereals. 
- To establish a complete interconnection and cataloguing system 
for the major culture collections in all Member ·States with 
on-line access, for a fee, by all research vorkers. A pilot 
scheme, involving the current BAP ~ontractors. should achieve--
these objectives by 1991. 
- To continue to develop appropriate methodology for an assess-
ment of the safety and ecological consequences of the release 
of genetically modified organisms. especially bacteria and 
viruses, in order to develop guidelines for best practice in 
the production and use of such organisms." 
1.2.2. Resolution of the European Parliament on biotechnology in Europe 
···············································~················ and the need for an integrated policy (1) 
········································~ 
In this resolution, which goes beyond the limits of R&D in bio-
technology, and upon which the Commission reported on 
30 October 1987 (2), the European Parliament acknowledged the 
"considerable success . of BEP. 1.n stimulating transnational 
cooperation between European laboratories and the t.a:aining of 
young scientists as well as coordinating research activities". 
The resolution noted. however. that BEP only had a limited 
budget and concentrated mainly on research· connected with 
agriculture and the food processing industry, and specified the 
priorities and essential features for future Community pro-
grammes in biotechnology. Among many specifications which, in 
certain cases, concerned other programmes of the Community 
(medical research, cooperation with the third world countries. 
AIM ••• ), the European Parliament underlined the necessity to 
give priority in future to projects studying the problems posed 
by the intentional release of genetically engineered micro-
organisms in the environment. 
(1) O.J. of the.European Communities, 16 February 1987. n° C 76/2S. 
(2) Half-yearly report on actions taken on Parliament's own initiative 
resolutions (January to June 1987). SP(87) 2461/2, 30 October 1987 1 
Commission of the European Communities. 
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1.2.3. The point of view of industrial organisations 
············································· 
The organisations which· ex~ressed opinions are 11&LeJ in 
Table 1. together with the titles of their reports. 
IRDAC. the industrial research and development advisory 
committee of the CEC. delivered the most detailed opinion on the 
content of BRIDGE. Many of its recommendations are in line with 
the programme proposed by the Commission. In particular. it was 
through a request of IRDAC W.P.5 "Biotechnology" that the 
research activities implemented in the framework of BAP on 
"second generation bioreactors" are not suggested to continue 
within BRIDGE. On the other hand. their recommendations to rank 
as top priorities protein engineering. or plant and microbial 
biotechnology (with increased emphasis on physiology and 
metabolism).· have been taken up entirely. 
The first recommendations submitted by EBCG with regard to 
safety evaluation (detection methods, micro-ecosystems, biologi-
cal containment, survival and speed of dispersal) have been 
integrated in the present proposal. Similarly, the various 
areas. including safety evaluation, which EBCG considered as 
priorities in its position paper "the approach of the 
biotechnology industry to BRIDGE" are parts of the present 
proposal. The . CUIC report on bio-informa.tics in Europe goes 
beyond. in ambition and in scope, the activities restricted in 
BRIDGE to the information needs of three sectors : protein 
design, genome sequencing, data banks and information networks. 
Other programmes have been defined, such as AIM (Advanced 
Informatics for Medicine), which will also contrib~te to the 
main objectives outlined by CEFIC. 
The "Green Industry Biotechnology Platfom" and a group of 16 
yeast related industries provided opinions which were restricted 
to the interest of defined indu~trbJ ... branche.r.- .• The correspon-
dence between their expectations and the provisions made Ly 
BRIDGE in the various sectors which they covered is extensive. 
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Table 1: References to opinions expressed by industrial organisations 
Industrial R&D Advisory Committee of the European Communities (IRDAC} 
"Opinion on future R&D programmes in the field of biotechnology", 
December 1987. 
-----=--=--====--=--=-===--==----=--==-----=-----------=--=------------=====------
European Biotechnology Co-ordination Group* (EBCG) 
"Safety Evaluation Through Risk Assessment in Biotechnology", March 1987. 
"The Approach of the Biotechnology Industry to BRIDGE", ·November 1987. 
European Council of Chemical Manufacturers Federation (CEFIC) 
"Bio-informatics in Euroi,e - An industry position paper", March 1987. 
Green Industry Biotechnology Platform (GIBiP) 
"Final opinion of GIBiP on the BRIDGE programme", April 1988. 
Consultation of yeast industries 
in "Sequencing the yeast genome, a detailed assessment", June 1988. 
* The members of EBCG are CEFIC, CIAA (Confederation of Food and Drink Indus-
tries of EEC), EFPIA (European Federation of Pharmaceutical Industries' 
Associations), GIFAP (International Group of National Associations of 
AgrochemJ.r11.l Manufacturers) and AMFEP (Association of Microbial. Food F~~yme 
Produce is). 
' ···.---· 
1.2.4. Opinion of the CGC "Biotechnology" 
. •.• .............................. . 
The present proposal was prepared with the constant help and 
feed-back of the CCC "Biotechnology" and, in particular, through 
the guidance of 10 specific ad hoe groups, each created by the 
CGC, for revi.ewing a specific sector or subsector of BRIDGE and 
making recommendations. At its meeting of 17 November 1988, the 
CGC reviewed an earlier version of the document and examined. at 
the same time. draft sugges_tions for amendments prepared by .... -...._ 
subgroups of IRDAC W.P. for biotechnology. The CGC thereafter-· -· · 
formulated final recommendations which are taken into account in 
the present proposal. 
7 -
\l 
2., OBJECTIVES AND ORIENTATIONS OF BRIDGE 
It is consid.!reu, on the basis of tht": :1s~e5c;mcr.t~ and recommen-
dations outlined above, that the objectives of the programme should 
be: 
~ to foster transnational research and to promote its 
catalytic effects, for accelerating the production of biological 
data, materials and methods' necessary for the safe and rational 
exploitation of useful organisms; 
- to place such data, materials and methods at the disposal 
of industry, agriculture and research centres and to encourage their 
exploitation; 
- to ensure that information generated under the programme 
is available for current discussions on the social acceptability of 
modern biotechnology; 
- to establish. through normative research, the scientific 
basis necessary for the establis.hment: of guidelines to regulate new 
and economically important production methods (including, in partic-
ular;· chose which are based upon the use of genetic engineering); 
- to take advantage of the scientific competences dispersed 
throughout the Community for contributing. via training and ·scien-
tific mobility. to the requirements of biotechnology operators in 
qualified scientific staff and in multidisciplinary combinations of 
expertise. 
Two approaches will be followed for the development of the pro-
gramme. 
2.1. Removal of bottlenecks resulting from gap§ in basic knowledge 
In most areas of biotechnology, there is clearly a need fo1 
embarking on exploratory research ventures, particularly when 
insufficient basic knowledge of organismal biology has been 
reducing the scope for applying molecular methods. The primary 
requirement in this prevalent situation is to increase .the multi-
disciplinarity of research by fostering temporary combinations of 
skills. The uncertainty of the outcome recommends a reasonable 
dosage of efforts and of supporting funds but its importance 
justifies an active partnership with industries, either for an 
active collaboration of efforts or for the exploitation of data, 
methods and materials originating from the research. Finally, the 
difficulty and complexity of the work calls for the catalytic 
mobilisation of competences throughout the entire Comm.unity. 
All these requi.rements can best be satisfied through the creation 
·.:-~of European Laboratories Without Walls (ELWs) similar ·to those 
which have been successfully promoted in the framework of BAP. The 
scientific content .for cooperative projects foreseeen for imple-
mentation by networks of ELWs is outlined in annex to the pro-
posal for a Council decision under the four headings: information 
infrastructure, enabling technologies, cellular b·iology and 
normative research. · 
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2.2. Removal of bottlenecks resulting from structural or scale con-
straints 
In several instances. the bottleneck to the exploitation of modern 
biology results from structural or scale constraints which could 
be overcome through a significant inves.tment of skills and re-
sources during a specific period. Community projects for the 
removal of such bottlenecks will. in many instances. represent the 
logical extension of activities initiated by European Laboratories 
Without Walls; they must. in all cases, clt·arly form part of the 
sectors outlined in annex to the proposal for a Cowicil decision 
and are to be defined, at the time the call for proposals is 
prepared, in close cooperation with the relevant advisory 
committee. "Sequencing of the yeast genome", "High resolut:ion 
automated microbial identif !cation" and "Molecular identification 
of new plant genes" are examples, among several others. of 
subjects which could be addressed in this way. 
2.3. Training 
It is proposed, on the basis of recent analyses (1. 2, 3) and of 
several consultations of experts and expert committees. to con-
tinue in BRIDGE the activities which have been shown. through BEP 
and BAP, to answer an essential need of the Community for scien-
tists trained in the complex areas of biotechnology. 
Training in BRIDGE will therefore involve: 
the establishment of training contracts for . junior and 
senior scientists with duration periods ranging from 6 to 24 
months. The scientific scope for these "training through research" 
activities will cover each of the specific areas outlined in annex 
to the proposal for a Council decision. 
- the organisation, as in BAP, of courses and summer 
schools in all areas of research where obvious training needs are 
identified during the implementation of the programme. 
(1) W. Dostal, Fast series n° 22 "New technology and development in 
employment". EUR 11386 EN, 1988. 
(2) D.J. Bennett "Manpower, Education and Training in Biotechnology" 
A.A.B.B., .London, 1988. 
(l) A. Dollacker, M. Olast • E. Magnien "The advertised demand for 
qualified staff in biotechnology-related fields : a statistical 
approach". DC XII, 1986 (draft report). 
- 9 = 
\3 
l. IMPLEMENTATION SCHEMES 
3.1. Cooperative networks pt'oje~c.1 ("N" projects) 
These projects, such as defined above in 2.1., will be based on 
the BAP model with a contribution of the Community ranging from 
200.000 - 400.000 ECU/year x project. Applications for support 
will be . requested to provide a very clear matrix of the tasks 
suggested for each of the laboratories presenting the proposal. 
Only closely integrated projects, obviously leading to the forma-
tion of·· an active European Laboratory Without Walls, will be 
considered for funding. 
When necessary, the Commission services will also organise trans-
national activities (visits, meetings, exchanges of information} 
between laboratories of high scientific level not involved in the 
implementation of science-led projects. It is expected that these 
laboratories, after a year or two of collaborations stimulated by-·: 
small financial contributions·will be ready, at the time BRIDGE is 
revised, to submit new trao.snational proposals for science-led 
projects. 
3. 2 •. Larger targeted projects ("T" projects) 
Support of the Commission to "T" projects, such as defined above 
in 2. 2. • may vary from l to 3 Mio ECU per year and per project. 
The manner in which the work is distributed and research funds are 
allocated to each participating laboratory will be specific to 
each project. Sequencing of the yeast genome, o~e of the 
"T" projects proposed above by the Commission, represents a case 
where Community funds are going to be allocated to very many 
laboratories working in one single project. 
3.3. Training 
Training activities will be pursued on the BAP model. For training 
through research, it is planned to attribute a number of training 
contracts to junior and senior scientists corresponding to an 
average of 160 man/year. Benchfees will be attributed to the host-
laboratories. 
4. MANAGEMENT PRINCIPLES 
4.1. Consultation of the advisory committee 
Preparation of tender documents for research and training activ-
ities, assessment of proposals and selection of trainees, evalua-
tion of results and d~ffusion of information on the programme will 
be made by the Commission in consultation with the rele·"ant 
advisory committee. 
4.2. Setting up of target-linked monitoring units 
Owing to the complexity and the wide diversity of scientific 
subjects that are ~ncompassed in the definition of modern bio-
technology, much specialised expertise appears required for the 
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proper management of all programme areas. Target-linked monitoring 
units should be established in association with each "T" project 
and. if needed. with certain groups of "N" projects. Each .monitor-
ing unit could be constituted. with the scientific officer er tu:-. 
Commission., through a list of experts from the Commission and from 
advisory committees. Each monitoring unit should follow the 
·progress of relevant projects towards specific goals of the 
corresponding part of the programme. and assist the Commission in 
various assessment and steering tasks. It should meet at least 
once a year. to analyse annual progress within the corresponding 
programme areas. and to report to the relevant adyisory committee. 
These monitoring units could constitute one of .the elements of a 
decentralised management system established progressively in the 
framework of the programme. 
4.3. Criteria for selection of research projects 
The selection of proposals will be carried out with the help of 
the advisory committee. The following criteria will be applied : 
- the technical competence of the proposer 
- the scientific interest of the .• proposal, its originality, 
its relevance to the scope of the programme and its feasibility 
(including ultimate· economic ·feasibility) 
- the likely contribution of the proposed research to 
safety, to the harmonisation of norms and to the economic strength 
and competitiveness of the European Communities 
- the intensity of transnational collaboration (proposals 
not originating from at least two laboratories located in 
different Member States will not be considered for funding) 
- the involvement of industry. through direct_ participa-
tion, co-financing. supply of materials, access to infrastruc-
tures, expression of interest for exploitation of research 
results ••• 
- when applicable. the assessment of risks possibly associ-
atetl to the research · proposed (each. contractant. will have .. ::o ·· 
adhere most strictly to the rules and recommendc1tions is.:iued on 
the matter in the Member State where the laboratory is located). 
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4.4. Relationships and cooperation with oth~r Comnunity or internation-
al K&D prograrmnes 
"BRIDGE contributes to the implementation of the subdivision "4.1. 
Biotechnology" of the Community Framework Programme for research 
and technological development. It is complemented by current and 
future specific programmes foreseeen under the subdivision "4.2. 
Agro-industrial technologies" and "4.3. Competitiveness of agri-
culture and management of agricultural resources.-'. The ties 
between BRIDGE and these actions are very narrow. particularly 
with regard to ECLAIR and FLAIR which lie directly downstream of 
the programme. 
Other relationships between BRIDGE and existing or future R&D 
Community activities are to be found in some of the areas covered 
by the programme "Environment". in the foreseen action for "Predi-
ctive Medicine". the "Science" plan. the programme "Science and 
Technique for Development". in ESPRIT (in particular area II.2 
"knowledge engineering") and in the demonstration projects f9r.the 
Energy Sector. 
In all these cases. close coordination will be assured to exploit 
natural complem.entarities between programmes and to avoid any 
unnecessary duplication. 
The generic and pre-competitive technological work envisaged for 
BRIDGE should, in the medium to long term range, create opportun-
ities for Eureka projects with commercial aims. 
The present links with the European Federation of Biotechnology 
· (participation of Commission staff to meetings of the Science 
Advisory and Executive EFB Committees. attendance of EFB represen-
tative,; to CEC worY.shops, support. as in June 1987. to t'~~~~-:: :,..-- • 
gani.sation of the European Congress on Biotechnology •• ,, ) w1i.&. t.i 
maintained and intensified. 
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ACTION II CONCERTATION 
1. ORIGIN AND AIMS 
Throughout the world, national administrations have recognised de 
facto that the interdisciplinary and multi-sectoral character of 
biotechnology demands inter-agency coordination for policy 
coherence. Recognising this, the Commission in 1984 established an 
inter-service Biotechnology Steering Committee, and supporting 
structures and activities; charged with implementing the range of 
priority actions for biotechnology defined in its previous 
communication to Council (1). leading to the preparation of 
Commission initiatives, such . as the recent proposals for 
biotechnology regulation (2). 
In March 1985, the Council Decision (3) establishing the Bio-
technology Action Programme provided a mandate for a concertation 
action involving the Member States. The Council mandate defined the 
objectives: 
"improving standards and capabilities in the life sciences, and 
enhancing the strategic effectiveness with which these are 
applied to the socia~ and economic objectives of the Community 
and its Member States". 
A list of supporting tasks was itemised, which can be summarised as: 
- worldwide monitoring and information gathering; analysis and 
evaluation; storage; and selective diffusion; 
- coordination and promotion of collaboration in policy areas 
affecting or affected by biotechnology, 
(i) - across the services of the Commission 
(ii) - between Commission and Member States, 
- scope for more specific initiatives on key biotechnology-related 
topics such as agriculture and environment, Third World develop-
ment, safety, public information, academic-industrial collabora-
tion, and social dimensions. 
Across all these areas, emphasis was placed on acting in conjunction 
with relevant services in the Community and the Member States, and 
through ad hoe, informal and flexible networks. 
(1) COM(83) 672 final/2, "Biotechnology in the Community", 
4 October 1983. 
(2) E.g. COM(86) 573 final, "A community Framework for the Regulation 
of Biotechnology", Communication from the Commission to the 
Council, 4 November 1986; COM(88) 160 final, "Proposal for a 
Council Directive on the contained use of genetically modified 
microorganisms" and "Proposal for a Council Directive on the 
deliberate release to the environment of genetically modified 
· . organisms", 4 May 1988; and COM(88) 165 final, "Proposal for a 
Council Directive on the Protection of Workers from the Risks 
related to Exposure to Biolog.ical Agents at Work". 5 April 1988. 
(3) O.J. L 83 of 25 March 1985. 
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2. CURRENT ACTIVITIES AND ACHIEVEMENTS 
Numerous activities have been initiated under these mandates., to 
provide a service of strategic awareness, analysis, recommendations 
for action, and supporting actions. Concertation is a service 
activity, to enable all Commission services., Member State agencies, 
or other actors involved in biotechnology to perform better or to 
coordinate better their actions. The following are examples of 
activities in which the concertation action has played a significant 
role 
(i) a documentation centre, now containing some 25.000 
policy-relevant papers on biotechnology, is used increas-
ingly by Commission and Member State colleagues, their 
advisers, consultants, researchers, and Parliamentary aids. 
Plans are in preparation to upgrade it, in particular to 
facilitate access and diffusion. Thousands of requests are 
met each year for information., advice and documentation; 
current activities are increasingly constrained by manpower 
and space limits. 
(ii) ad hoe studies and workshops have led to actions on 
recommendations 
the "BICEPS" planning exercise (Bio-Informatics : Collaborative 
European Programmes and Strategy (1); provided foundations for 
reinforcing bio-informatics in BAP and BRIDGE, and for the AIM 
programme (Advanced Infonnatics in Medicine); 
- various studies., consultative meetings., a Commission discussion 
paper (2) and a call for expressions of interest prepared the 
proposal for the ECLAIR and~ programmes (3, 4); 
- studies arising from the work of the Task Force for Biotechnology 
Information have led to concrete recommendations., well-supported 
by industry., for a European biotechnology information policy (5); 
(1) BICEPS summary report available, and 15 supporting study or work-
shop reports. 
(2) .COM(86) 221/2., Discussion Paper., "Biotechnology in the Community : 
Stimulating Agro-Industrial Development", 15 April 1986. 
(3) COM(87) 66 7., Proposal for a Council Decision to adopt a first 
multi-annual programme ( 1988-1993) for biotechnology-based agro-
industrial research and technological development "ECLAIR" (Eur-
opean Collaborative Linkage of Agriculture and Industry through 
Research), 18 December 1987. 
(4) COM(88) 351., Proposal for a Council Decision to adopt a multi-
annual research and development programme in food science and 
technology (1989 to mid-1993} FLAIR (Food-Linked Agro-Industrial 
Research}, 24 June 1988. 
(5) "The Role of Information Technology and Services in · the Future. 
Competitiveness of Europe's Bio-industries", report prepared for 
the Commission, January 1988., by ASFRA consultants. 
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(111) - secretariat of interservice groups such as the 
Biotechn~logy Steering Committee, BRIC, and Bio-RDD. 
These and other activities are pursued in implementation of the 
multi-service strategy defined in 1983. 
3. OPINIONS, EVALUATION AND RECOMMENDATIONS 
The above initiatives, both in the general aim of strategic coher-
ence and the specific examples cited., are in accordance with the 
recommendations of IRDAC (l}. The EVALUATION PANEL (2) recommended 
that 
"The concertation activity should also be expanded in line with the 
general growth of the biotechnology research programme, to about 10% 
of the total budget of BRIDGE"; and 
"should concentrate on four major tasks., of which the last is new: 
(1) The coordination of the Commission's approach to bio-
technology, including the dissemination of information in-
ternally., and the formulation of proposals for future initia-
tives. 
(ii) The concertation of biotechnology activities of MeQber States. 
(iii) The provision of information on the advantages, . limitations 
and safety of biotechnology to politicians., scientists and the 
general public in the Community and in Associated States under 
the tome Convention. 
(iv) Activities designed to promote the formation and growth of 
small and medium-sized biotechnology firms." 
These recommendations are generally acceptable to the Commission, 
and in the proposals for the future of the concertation action, the 
objectives, tasks and resource requirements have taken these recom-
mendations into account. Current tasks have been reviewed and 
focussed more closely towards the above priorities; in line also 
with the recommendations of the CGC (Biotechnology). 
(1) IRDAC, Industrial R&D Advisory Committee of the Commission of the 
European Communities, "Opinion on future R&D programmes in the 
field of biotechnology", December 1987. 
(2) "Evaluation of the Biomolecular Engineering Programme II BEP 
(1982-1986) and the Biotechnology Action Programme, BAP 
(1985-1989}", expert panel, Summer 1988. 
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4. OBJECTIVES AND PRIORITIES FOR CONCERTATION 
The objectives for concertation originally defined by the March 1985 
Council Decision (see §1 above) remain pertinent, but their effec-
tive pursuit through specific actions and tasks will be updated to 
take account of: 
(i) - worldwide developments in biotechnology over the last few 
years - for example, the increased importance of worldwide 
electronic networking, databanks, and related information 
infrastructure; the rapidly growing competitive challenge 
from newly industrialising countries; 
(ii} the recent and likely future evolution of Community and 
Member State policies related to or influenced by bio-
technology - for example, the launching of che agro-
industrial programmes ECLAIR and FLAIR will diminish the 
need for the concertation action to promote new activities 
itt this area. 
The im.pleinentation o·f the supporting tasks (·see § 1) will thus be 
modified, taking into account the recommendations of the Evaluation 
Panel, IRDAC, the progrclDIDle management committee, and other needs 
identified via the networks (industrial, scientific, public interest 
etc.). In particular, collaboration will be reinforced with those 
respon$ible for bi-ot.echnology~related matters in Member State 
administrations and agencies. 
5 • . IMPLEMENTATION 
Implementation of the concertation action will be through in-house 
work, in collaboration with Commission services, Member· States and 
other interested bodies; based on the continued development and more 
effective exploitation of the monitoring, information base, informa-
tion· .di.ffusion and analysis activities; the commissioning of study 
reports, the organisation of workshops and meetings, and support for 
"Task Force" activities around the aims outlined above. 
Although some staff increase are seen as essential to cope with the 
growing volume of biotechnology activities, maximum use will be made 
of external services, and of collaborative activities with bio-
technology-related units in Member State administrations and public 
agencies. The secondment of Member State staff over periods 
typically of l to 3 years will be particularly encouraged, in order 
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